# Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus

> **NCT00714116** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 30 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** SBI-087

## Key facts

- **NCT ID:** NCT00714116
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00714116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00714116, "Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00714116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*